

RUXOLITINIB

EFFECTIVE DATE: 2015-05-20

1 Product and Company Identification

- 1.1 Product Name: Ruxolitinib
- **1.2 Product Identifier:**, (3R)-3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]propanenitrile
- **1.3 Catalog Number:** 73402, 73404
- 1.4 Product Use: Laboratory Chemical
- 1.5
 Manufacturer/Supplier:
 STEMCELL Technologies

 Suite 500-1618
 Station Street

 Vancouver, British
 Columbia

 V6A
 1B6
- **1.6 In Case of Emergency Call:** 1-800-667-0322

2 Hazards Identification

2.1 Classification of the substance or mixture

Skin Corrosion/Irritation, Category 2 Serious Eye Damage/Eye Irritation, Category 1 Target Organ Systemic Toxicity (repeated exposure), Category 2 Toxic To Reproduction, Category 2 Acute Toxicity: Oral, Category 4

2.2 Label elements

Pictogram



Danger Hazard statement(s) H315 Causes skin irritation. H318 Causes serious eve damage H373 May cause damage to organs through prolonged or repeated exposure. H361 Suspected of damaging fertility or the unborn child. Harmful if swallowed. H302 Precautionary statement(s) P264 Wash hands thoroughly after handling. P280 Wear protective gloves/clothing and eye/face protection as specified by the manufacturer/supplier or the competent authority. P260 Do not breathe dust/fume/gas/mist/vapours/spray. P201 Obtain special instructions before use. P202 Do not handle until all safety precautions have been read and

73402_73404-SDS_GHS

understood.



RUXOLITINIB

EFFECTIVE DATE: 2015-05-20

	P281	Use personal protective equipment as required.
	P270	Do not eat, drink or smoke when using this product.
	P302+352	IF ON SKIN: Wash with plenty of soap and water.
	P332+313	If skin irritation occurs, get medical advice/attention.
	P362	Take off contaminated clothing and wash before re-use.
	P305+351+338	IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.
	P310	Immediately call a POISON CENTER or doctor/physician.
	P314	Get medical attention/advice if you feel unwell.
	P308+313	IF exposed or concerned: Get medical attention/advice.
	P301+312	IF SWALLOWED: Call a POISON CENTER or doctor/physician if you feel unwell.
	P330	Rinse mouth.
2.3	Other hazards	No data available

3 Composition / Information on Ingredients

3.1 Substances

Synonyms	βR-cyclopentyl-4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazole- 1-propanenitrile; INCB 018424; INC 424
Molecular formula	C ₁₇ H ₁₈ N ₆
Molecular weight	306.4

Hazardous Components (Chemical Name)	CAS #	Concentration	EC #
(3R)-3-cyclopentyl-3-[4-(7H-pyrrolo[2,3- d]pyrimidin-4-yl)pyrazol-1-yl]propanenitrile	941678-49-5	100%	N/A

4 First Aid Measures

4.1 Description of first aid measures

4.1.1 If inhaled

Remove to fresh air. If not breathing, give artificial respiration or give oxygen by trained personnel. Get immediate medical attention.

4.1.2 In case of skin contact

Immediately wash skin with soap and plenty of water for at least 15 minutes. Remove contaminated clothing. Get medical attention if symptoms occur. Wash clothing before reuse.

4.1.3 In case of eye contact

Hold eyelids apart and flush eyes with plenty of water for at least 15 minutes. Have eyes examined and tested by medical personnel.

4.1.4 If swallowed

Wash out mouth with water provided person is conscious. Never give anything by mouth to an unconscious person. Get medical attention. Do NOT induce vomiting unless directed to do so by medical personnel.



RUXOLITINIB

EFFECTIVE DATE: 2015-05-20

- **4.2 Most important symptoms and effects, both acute and delayed** The toxicological properties of this product have not been fully evaluated.
- **4.3 Indication of any immediate medical attention and special treatment needed** No data available

5 Fire Fighting Measures

5.1 Extinguishing Media

5.1.1 Suitable Extinguishing Media

Use alcohol-resistant foam, carbon dioxide, water, or dry chemical spray. Use water spray to cool fire-exposed containers.

5.1.2 Unsuitable Extinguishing Media

A solid water stream may be inefficient.

5.2 Special hazards arising from the substance or mixture

5.2.1 Flammable Properties and Hazards

- No data available
- 5.2.2 Flash Pt No data available
- 5.2.3 Autoignition Pt No data available
- 5.2.4 Explosive Limits

LEL: No data available

UEL: No data available

5.2.5 Hazardous Combustion Products No data available

5.3 Fire Fighting Instructions

As in any fire, wear self-contained breathing apparatus pressure-demand (NIOSH approved or equivalent), and full protective gear to prevent contact with skin and eyes.

6 Accidental Release Measures

6.1 Personal precautions, protective equipment and emergency procedures

Avoid raising and breathing dust, and provide adequate ventilation.

As conditions warrant, wear a NIOSH approved (or equivalent) self-contained breathing apparatus, or respirator, and appropriate personal protection (rubber boots, safety goggles, and heavy rubber gloves).

6.2 Environmental precautions

Take steps to avoid release into the environment, if safe to do so.

6.3 Methods and materials for containment and cleaning up

Contain spill and collect, as appropriate.

Transfer to a chemical waste container for disposal in accordance with local regulations.



RUXOLITINIB

EFFECTIVE DATE: 2015-05-20

7 Handling and Storage

7.1 Precautions for safe handling

Avoid breathing dust/fume/gas/mist/vapours/spray. Avoid prolonged or repeated exposure.

7.2 Conditions for safe storage

Keep container tightly closed. Store in accordance with information listed on the product insert.

8 Exposure Controls/Personal Protection

8.1 Exposure limits

Component	CAS #	Value	Control parameters
(3R)-3-cyclopentyl-3-[4-(7H-pyrrolo[2,3- d]pyrimidin-4-yl)pyrazol-1-yl]propanenitrile	941678-49-5	No data available	No data available

8.2 Engineering controls

Use process enclosures, local exhaust ventilation, or other engineering controls to control airborne levels below recommended exposure limits.

8.3 Personal protective equipment

8.3.1 Eye/face protection

Safety glasses

8.3.2 Skin protection

Compatible chemical-resistant gloves Lab coat

8.3.3 Respiratory protection

NIOSH (US) or CEN (EU) approved respirator, as conditions warrant.

8.3.4 General hygiene considerations

Do not take internally.

Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower.

Wash thoroughly after handling.

8.3.5 Environmental exposure controls

No data available

9 Physical and Chemical Properties

9.1 Information on basic physical and chemical properties

Appearance	A crystalline solid
Odour	No data available
Odour threshold	No data available
рН	No data available
Melting point/freezing point	No data available



RUXOLITINIB

EFFECTIVE DATE: 2015-05-20

Boiling point/boiling range	No data available
Flash point	No data available
Evaporation rate	No data available
Flammability (solid, gas)	No data available
Upper/lower flammability or explosive limits	No data available
Vapour pressure	No data available
Vapour density	No data available
Relative density	No data available
Solubility	~0.5 mg/mL in 1:1 EtOH:PBS (pH 7.2); ~13 mg/mL in EtOH; ~5 mg/mL in DMF & DMSO
Partition coefficient: n-octanol/water	No data available
Auto-ignition temperature	No data available
Decomposition temperature	No data available
Viscosity	No data available

10 Stability and Reactivity

10.1 Reactivity	No data available
10.2 Chemical stability	Stable
10.3 Possibility of hazardous reactions	No data available
10.4 Conditions to avoid	Protect from heat and light
10.5 Incompatible materials	Acids Bases
10.6 Hazardous decomposition products	Carbon dioxide Carbon monoxide Nitrogen Oxides

11 Toxicological Information

11.1 Acute toxicity

No data available
No data available
No data available
No data available

- **11.2 Skin corrosion/irritation** No data available
- **11.3 Serious eye damage/eye irritation** No data available
- **11.4 Respiratory and/or skin sensitization** No data available
- 11.5 Germ cell mutagenicity No data available
- 11.6 Carcinogenicity



Ruxolitinib

EFFECTIVE DATE: 2015-05-20

IARC: No component of this product present at levels greater than or equal to 0.1% is identified as probable, possible or confirmed human carcinogen by IARC. No component of this product present at levels greater than or equal to 0.1% is ACGIH: identified as a carcinogen or potential carcinogen by ACGIH. NTP: No component of this product present at levels greater than or equal to 0.1% is identified as a known or anticipated carcinogen by NTP. OSHA: No component of this product present at levels greater than or equal to 0.1% is identified as a carcinogen or potential carcinogen by OSHA. 11.7 Reproductive toxicity No data available 11.8 Specific target organ toxicity - single exposure No data available 11.9 Specific target organ toxicity - repeated exposure No data available 11.10 Aspiration hazard No data available **11.11 Potential health effects** Inhalation: Material may be irritating to the mucous membranes and upper respiratory tract. May be harmful by inhalation. May cause respiratory system irritation. Ingestion: Harmful if swallowed. Skin: Causes skin irritation. May be harmful by skin absorption. Eves: Risk of serious damage to eyes 11.12 Signs and symptoms of exposure May cause damage to organs through prolonged or repeated exposure. Suspected of damaging fertility or the unborn child. Exposure may cause: abnormal clotting, bruising, and/or bleeding. Exposure may cause: Dizziness, drowsiness, dyspnea (breathing difficulty), headache, nausea, skin rash, vomiting, and weakness. To the best of our knowledge, the chemical, physical, and toxicological properties have not been thoroughly investigated. 11.13 RTECS # No data available

12 Ecological Information

may cause

13 Disposal Considerations



RUXOLITINIB

EFFECTIVE DATE: 2015-05-20

13.1 Waste disposal method

Dispose in accordance with local, provincial/state, and federal regulations.

13.2 Contaminated packaging Dispose of as unused product.

14 Transport Information

14.1	UN number	No data available		
14.2	UN proper shipping name	DOT ADR/RID IMDG IATA	Not dangerous goods Not dangerous goods Not dangerous goods Not dangerous goods	
14.3	Transport hazard class(es)	No data ava	ailable	
14.4	Packing group	No data available		
14.5	Environmental hazards	No data available		
14.6	Special precautions	No data ava	ailable	

15 Regulatory Information

15.1 US EPA SARA Title III

Hazardous Components (Chemical Name)	CAS #	Sec.302 (EHS)	Sec.304 RQ	Sec.313 (TRI)
(3R)-3-cyclopentyl-3-[4-(7H-pyrrolo[2,3- d]pyrimidin-4-yl)pyrazol-1-yl]propanenitrile	941678-49-5	No	No	No

15.2 Other US EPA or State Lists

Hazardous Components (Chemical Name)	CAS #	CAA HAP, ODC	CWA NPDES	TSCA	CA PROP.65
(3R)-3-cyclopentyl-3-[4-(7H-pyrrolo[2,3- d]pyrimidin-4-yl)pyrazol-1-yl]propanenitrile	941678-49-5	No	No	No	No

15.3 EU

This SDS was prepared in accordance with Regulation (EC) No.1272/2008 and European Directive 67/548/EEC as amended.

15.4 Canada

Not WHIMIS Controlled.

This SDS was prepared in accordance with Hazardous Products Regulations (HPR) and WHMIS 2015.

16 Other Information

16.1	Prepared by:	Quality Control, STEMCELL	Technologies Inc.
------	--------------	---------------------------	-------------------

- 16.2 Revision: N/A
- **16.3 Notice:** The above information is believed to be correct but does not purport to be all inclusive and shall be used only as a guide. STEMCELL Technologies Inc. shall not be held liable for any damage resulting from handling or from contact



RUXOLITINIB	EFFECTIVE DATE: 2015-05-20
	with the product. The information contained in this Safety Data Sheet (SDS) is current as of the Effective Date shown in this document and may be subject to amendment by STEMCELL Technologies Inc.
16.4 Disclaimer:	THIS PRODUCT IS FOR RESEARCH USE ONLY. NOT INTENDED FOR

HUMAN OR ANIMAL DIAGNOSTIC OR THERAPEUTIC USES.